Trial Profile
Phase 1/2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Clinical Study for the Safety, Tolerability, and Efficacy of IV MTP-131 for Mitochondrial Myopathy in Genetically Confirmed Mitochondrial Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Elamipretide (Primary)
- Indications Mitochondrial myopathies
- Focus Therapeutic Use
- Acronyms MMPOWER
- Sponsors Stealth BioTherapeutics
- 02 Mar 2018 Results published in the Neurology
- 12 Sep 2016 According to Stealth BioTherapeutics media release, the company hopes to use results of this study and MMPOWER 2 study to engage in discussions with regulators to develop the design for a Phase 3 trial in primary mitochondrial disease
- 17 Jun 2016 Primary endpoint has been met. (Change in distance walked (meters) on the 6-minute walk test (6MWT) for higher dose (0.25 mg/kg/hr)), as per Stealth BioTherapeutics media release.